KRAS mutation found in over 90% of pancreatic cancer patients and about 30–45% of colorectal cancer (CRC) patients. KRAS mutant cancer patients are becoming less responsive to chemotherapy and resistance to EGFR-target anticancer drugs, and no drug is available to fulfill these unmet needs in present. sGal-9 can treat KRAS mutant CRC and pancreatic cancer effectively by complex interaction with cancer cell cytotoxicity mechanism, cancer cell metastasis suppression, and selective KRAS cancer cell apoptosis.
sGal-9 anti-cancer MOA
- Inhibition of EGFR pathway
- Cancer cell metastasis inhibition
EGFR and Downstream Genetic Alterations in KRAS/BRAF and PI3K/AKT Pathways in
Colorectal Cancer Implications for Targeted Therapy - Marianne Berg - Discovery Medicine.
DOI 10.1002/med.20249 - Therapeutic Potential of Galectin-9 in Human Disease
